HLS Therapeutics, a pharmaceutical company specializing in psychiatric and cardiovascular treatments, has recently announced a new Credit Agreement with National Bank of Canada. This Agreement provides HLS with committed credit facilities totaling up to CAD$107 million (approximately USD$77.5 million). The National Bank serves as the administrative agent and lead arranger, alongside syndicate members including Toronto-Dominion Bank, Royal Bank of Canada, and Innovation Federal Credit Union. This new Agreement replaces HLS’s previous credit facility with JP Morgan Chase Bank and offers improved terms and financial flexibility, with a maturity date set for August 19, 2029.
The Credit Agreement comprises a term credit facility of CAD$79 million, a delayed draw facility of CAD$14 million, and a revolving credit facility of CAD$14 million. Additionally, there is an option for HLS to increase these facilities through an uncommitted accordion facility of up to CAD$40 million, subject to lender agreement. Interest on the Agreement is calculated based on the Canadian Overnight Repo Rate Average (CORRA) plus a variable rate depending on the Company’s leverage ratio. HLS stands to benefit from reduced interest expenses compared to its prior credit agreement, with interest rate spreads 25-50 basis points lower.
The decision to denominate the debt in Canadian dollars serves as a natural currency hedge for HLS, given its primarily Canadian operations. This choice, coupled with the current interest rate environment, is expected to result in significant interest rate savings for the company. HLS’s CFO, John Hanna, expressed confidence in the new credit agreement, highlighting its alignment with the company’s financial position and capital allocation priorities, such as share buybacks and portfolio expansion. HLS, established in 2015, focuses on acquiring and commercializing pharmaceutical products in the North American market, particularly in the central nervous system and cardiovascular therapeutic areas.
Forward-looking statements included in the release shed light on HLS’s growth strategies and market expectations. HLS’s management emphasizes the pursuit of additional product opportunities and growth avenues, supported by a seasoned team with a successful track record in pharmaceuticals. However, it’s crucial to acknowledge the inherent risks associated with the specialty pharmaceutical industry, regulatory approvals, and economic factors that could impact HLS’s future performance. The company advises caution in relying too heavily on forward-looking statements, encouraging a thorough review of associated risks and assumptions in their regulatory filings.
In conclusion, HLS Therapeutics’ new Credit Agreement marks a significant milestone in the company’s journey towards sustained growth and operational excellence. By securing enhanced credit facilities with favorable terms, HLS is poised to strengthen its financial position, drive innovation in pharmaceutical offerings, and expand its market presence. The alignment of the Agreement with HLS’s strategic objectives underscores a clear path for value creation and long-term success in the pharmaceutical landscape.
- HLS’s new Credit Agreement with National Bank enhances financial flexibility and cash flow.
- Denominating the debt in Canadian dollars provides a natural currency hedge for HLS.
- Forward-looking statements highlight HLS’s growth strategies and market expectations.
- HLS emphasizes caution regarding risks associated with the pharmaceutical industry.
Tags: regulatory
Read more on cantechletter.com